Atreca is a privately held biotechnology company developing novel therapeutics based on a deep understanding of the human immune response, with lead portfolio programs focused on applications in cancer treatment. We measure and analyze the structure of clinically successful immune responses to identify antibodies, T cell receptors (TCRs), and targets that are key to successful treatment outcomes in patients. Based on these capabilities, Atreca is advancing therapeutic candidates that can drive and focus the activity of the immune responses unleashed by checkpoint inhibitors and immune activators, thus optimizing therapeutic outcomes in cancer patients.
Atreca’s proprietary Immune Repertoire Capture™ (IRC™) technology profiles a patient’s immune response at the single-cell level at very high throughput without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. This delivers an unparalleled quantitation of the adaptive immune response, transforming the discovery and development of therapeutics, vaccines, and diagnostics in a variety of therapeutic areas where immune functionality is a key contributor to clinical outcomes. IRC™ technology has been validated in partnerships with major pharmaceutical companies, non-profit foundations, academic institutions, and the US Government.
Atreca’s leadership and advisors have extensive expertise in product development, operations, and commercialization, and have successfully pioneered next-generation approaches to immunotherapy across diverse therapeutic areas. The Company also is supported by leading life sciences and strategic investors, most recently announcing completion of a funding round in October 2015.